SETTING: Harare's high density suburbs. OBJECTIVES: To investigate the burden, duration and risk factors for prevalent tuberculosis (TB) and explore potential control strategies. METHODS: Randomly selected adults had TB culture, symptom screen and human immunodeficiency virus (HIV) serology. Prevalent TB was defined as undiagnosed or still culture-positive. Notification data and HIV prevalence in TB out-patients were used to estimate duration of infectiousness (prevalence/estimated incidence). RESULTS: Among 10 092 participants, 40 (0.40%, 95%CI 0.28-0.54) had prevalent smear-positive TB. HIV (adjusted odds ratio [aOR] 3.1, 95%CI 1.6-6.3, population attributable fraction [PAF] 33%), male sex (aOR 3.1, 95%CI 1.5-6.4, PAF 40%), and overcrowding (PAF 34%) were significant risk factors, with past TB treatment significant for HIV-negative participants only (PAF 7%). Recent household TB contact was not significant (PAF 10%). HIV prevalence was 21.1%; 76.9% of HIV-positive participants were previously untested. Duration of infectiousness was at least 18 weeks in HIV-positive and approximately 1 year in HIV-negative patients. CONCLUSIONS: Overcrowding, male sex and HIV infection were major risk factors for prevalent smear-positive TB. Reducing diagnostic delay may have greater potential to improve the control of prevalent TB than interventions targeted at household contacts, TB treatment outcomes, or TB-HIV interventions under current levels of awareness of HIV status.
SETTING: Harare's high density suburbs. OBJECTIVES: To investigate the burden, duration and risk factors for prevalent tuberculosis (TB) and explore potential control strategies. METHODS: Randomly selected adults had TB culture, symptom screen and human immunodeficiency virus (HIV) serology. Prevalent TB was defined as undiagnosed or still culture-positive. Notification data and HIV prevalence in TB out-patients were used to estimate duration of infectiousness (prevalence/estimated incidence). RESULTS: Among 10 092 participants, 40 (0.40%, 95%CI 0.28-0.54) had prevalent smear-positive TB. HIV (adjusted odds ratio [aOR] 3.1, 95%CI 1.6-6.3, population attributable fraction [PAF] 33%), male sex (aOR 3.1, 95%CI 1.5-6.4, PAF 40%), and overcrowding (PAF 34%) were significant risk factors, with past TB treatment significant for HIV-negative participants only (PAF 7%). Recent household TB contact was not significant (PAF 10%). HIV prevalence was 21.1%; 76.9% of HIV-positive participants were previously untested. Duration of infectiousness was at least 18 weeks in HIV-positive and approximately 1 year in HIV-negative patients. CONCLUSIONS: Overcrowding, male sex and HIV infection were major risk factors for prevalent smear-positive TB. Reducing diagnostic delay may have greater potential to improve the control of prevalent TB than interventions targeted at household contacts, TB treatment outcomes, or TB-HIV interventions under current levels of awareness of HIV status.
Authors: Robin Wood; Keren Middelkoop; Landon Myer; Alison D Grant; Andrew Whitelaw; Stephen D Lawn; Gilla Kaplan; Robin Huebner; James McIntyre; Linda-Gail Bekker Journal: Am J Respir Crit Care Med Date: 2006-09-14 Impact factor: 21.405
Authors: J Desormeaux; M P Johnson; J S Coberly; P Losikoff; E Johnson; R Huebner; L Geiter; H Davis; J Atkinson; R E Chaisson; R Boulos; N A Halsey Journal: Bull Pan Am Health Organ Date: 1996-03
Authors: P Godfrey-Faussett; H Kaunda; J Kamanga; S van Beers; M van Cleeff; R Kumwenda-Phiri; V Tihont Journal: Int J Tuberc Lung Dis Date: 2002-09 Impact factor: 2.373
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12
Authors: David Guwatudde; Sarah Zalwango; Moses R Kamya; Sara M Debanne; Mireya I Diaz; Alphonse Okwera; Roy D Mugerwa; Charles King; Christopher C Whalen Journal: Bull World Health Organ Date: 2004-01-20 Impact factor: 9.408
Authors: Saskia den Boon; Schalk W P van Lill; Martien W Borgdorff; Donald A Enarson; Suzanne Verver; Eric D Bateman; Elvis Irusen; Carl J Lombard; Neil W White; Christine de Villiers; Nulda Beyers Journal: Emerg Infect Dis Date: 2007-08 Impact factor: 6.883
Authors: Helen Ayles; Albertus Schaap; Amos Nota; Charalambos Sismanidis; Ruth Tembwe; Petra De Haas; Monde Muyoyeta; Nulda Beyers Journal: PLoS One Date: 2009-05-19 Impact factor: 3.240
Authors: Leonardo Martinez; Renu Verma; Julio Croda; C Robert Horsburgh; Katharine S Walter; Nicholas Degner; Keren Middelkoop; Anastasia Koch; Sabine Hermans; Digby F Warner; Robin Wood; Frank Cobelens; Jason R Andrews Journal: Eur Respir J Date: 2019-06-27 Impact factor: 16.671
Authors: Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman Journal: Clin Microbiol Rev Date: 2018-07-18 Impact factor: 26.132
Authors: James R Hargreaves; Delia Boccia; Carlton A Evans; Michelle Adato; Mark Petticrew; John D H Porter Journal: Am J Public Health Date: 2011-02-17 Impact factor: 9.308
Authors: Peter J Dodd; Kerry A Millington; Azra C Ghani; Junior Mutsvangwa; Anthony E Butterworth; Ajit Lalvani; Elizabeth L Corbett Journal: Am J Epidemiol Date: 2010-04-09 Impact factor: 4.897
Authors: Elizabeth L Corbett; Tsitsi Bandason; Trinh Duong; Ethel Dauya; Beauty Makamure; Gavin J Churchyard; Brian G Williams; Shungu S Munyati; Anthony E Butterworth; Peter R Mason; Stanley Mungofa; Richard J Hayes Journal: Lancet Date: 2010-10-09 Impact factor: 79.321